trending Market Intelligence /marketintelligence/en/news-insights/trending/PIKlEI9WLK6E-kmZQv2YlA2 content esgSubNav
In This List

ImmunoVaccine cancer drug combo well-tolerated in early-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ImmunoVaccine cancer drug combo well-tolerated in early-stage study

ImmunoVaccine Inc. said a combination of its lead drug candidate DPX-Survivac with Incyte Corp.'s epacadostat was well-tolerated in patients with advanced ovarian cancer in a phase 1b trial.

Top-line clinical data from the study, which included 10 evaluable patients, also showed a decrease in the tumor size in three of the patients.

The company said a majority of the patients in the trial exhibited T-cell activation, assisting immune response in the body.

"Individuals with recurrent ovarian cancer, in particular, have not yet benefited from immunotherapy treatment breakthroughs in the way that those with other hard-to-treat cancers have. We believe that these clinical results reported thus far for this combination immunotherapy in this patient population are promising," ImmunoVaccine CEO Frederic Ors said in a statement.

The second dosing cohort is ongoing and is expected to enroll 16 to 40 patients in total. ImmunoVaccine expects to provide a clinical update on the second dosing cohort in the first half of 2018 and investigators are also planning to submit the study findings for scientific publication.

DPX-Survivac is designated as an orphan drug by the European Medicines Agency. It also received fast-track status from the U.S. Food and Drug Administration as maintenance therapy in individuals with advanced ovarian, fallopian tube and peritoneal cancer.